Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
R413337-5mg | 5mg | In stock | $88.90 | |
R413337-25mg | 25mg | In stock | $400.90 | |
R413337-100mg | 100mg | In stock | $642.90 | |
R413337-250mg | 250mg | In stock | $1,446.90 |
GNRH Receptor Antagonists
Synonyms | Relugolix|737789-87-6|TAK-385|Orgovyx|TAK 385|1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea|UNII-P76B05O5V6|P76B05O5V6|Relugolix(TAK-385)|CH |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Relugolix (RVT-601, TAK-385) is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) with IC50 of 0.33 nM and 0.32 nM for human GnRHR and monkey GnRHR, respectively. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Gonadotropin-releasing hormone receptor antagonist |
Product Description | Information Relugolix Relugolix (RVT-601, TAK-385) is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) with IC50 of 0.33 nM and 0.32 nM for human GnRHR and monkey GnRHR, respectively. Targets monkey GnRHR (Cell-free assay); human GnRHR (Cell-free assay) 0.32 nM; 0.33 nM In vitro Relugolix (TAK-385) possesses higher affinity and potent antagonistic activity for human (binding IC50=0.33 nM in the presence of serum) and monkey GnRH receptor (IC50=0.32 nM), but has low affinity for the rat GnRH receptor (IC50=9800 nM). In vivo TAK-385 acts as an antagonist for human GnRH receptor in vivo and daily oral administration potently, continuously and reversibly suppresses the hypothalamic-pituitary-gonadal axis. |
ALogP | 4.623 |
---|---|
HBD Count | 2 |
Rotatable Bond | 9 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea |
---|---|
INCHI | InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40) |
InChi Key | AOMXMOCNKJTRQP-UHFFFAOYSA-N |
Canonical SMILES | CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC |
Isomeric SMILES | CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC |
PubChem CID | 10348973 |
Molecular Weight | 623.63 |
CAS Registry No. | 737789-87-6 |
---|---|
PubChem CID | 10348973 |
ChEMBL Ligand | CHEMBL1800159 |
DrugCentral Ligand | 5432 |
GPCRdb Ligand | relugolix |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
H2218534 | Certificate of Analysis | Jun 18, 2022 | R413337 |
H2218535 | Certificate of Analysis | Jun 18, 2022 | R413337 |
H2218536 | Certificate of Analysis | Jun 18, 2022 | R413337 |
H2218756 | Certificate of Analysis | Jun 18, 2022 | R413337 |
Solubility | Solubility (25°C) In vitro DMSO: 61 mg/mL (97.81 mM); Water: Insoluble; Ethanol: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 61 |
DMSO(mM) Max Solubility | 97.8144091849334 |
Water(mg / mL) Max Solubility | <1 |
Pictogram(s) | GHS08 |
---|---|
Signal | Warning |
Hazard Statements | H361:Suspected of damaging fertility or the unborn child H371:May cause damage to organs |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P270:Do not eat, drink or smoke when using this product. P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice. P308+P316:IF exposed or concerned: Get emergency medical help immediately. |
1. Miwa K, Hitaka T, Imada T, Sasaki S, Yoshimatsu M, Kusaka M, Tanaka A, Nakata D, Furuya S, Endo S et al.. (2011) Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor.. J Med Chem, 54 (14): (4998-5012). [PMID:21657270] |